Warner Biddle

Stories

Kyverna touts year-long miv-cel data as Novartis, Bristol Myers pause autoimmune CAR-T trials

As of September 2026: Leading miv-cel's FDA filing and launch preparations

Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.

Updated Sep 24

Notable Quotes

We're seeing really dramatic clinical results, but we're also seeing no high-grade CRS, no high-grade ICANS, no instances of IEC-HS side effects.

from Kyverna touts year-long miv-cel data as Novartis, Bristol Myers pause autoimmune CAR-T trials · Updated Sep 24

We are using a traditional, well-established, validated manufacturing process that we've now established over 100+ patients.

from Kyverna touts year-long miv-cel data as Novartis, Bristol Myers pause autoimmune CAR-T trials · Updated Sep 24